Mohammed A. Alghamdi

Mohammed A. Alghamdi

Auto-generated profile, based on publicly available information

Mohammed A. Alghamdi

Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
BXBin Xu
Bin Xu
TFTalia L. Fuchs
Talia L. Fuchs
SASara Ahmadi
Sara Ahmadi
MAMohammed Alghamdi
Mohammed Alghamdi
BABayan Alzumaili
Bayan Alzumaili
RGRonald Ghossein
Ronald Ghossein
PURPOSE: Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor (NET) arising from the calcitonin-producing C cells. Unlike other NETs, there is no widely accepted pathologic grading scheme. In 2020, two groups separately developed slightly different schemes (the Memorial Sloan Kettering Cancer Center and Sydney grade) on the basis of proliferative activity (mitotic index and/or Ki67 proliferative index) and tumor necrosis. Building on this work, we sought to unify and validate an internationally accepted grading scheme for MTC. PATIENTS AND METHODS: Tumor tissue from 327 patients with MTC from five centers across the United States, Europe, and Australia were reviewed for mitotic activity, Ki67 proliferative index, and necrosis using uniform criteria and blinded to other clinicopathologic features. After reviewing different cutoffs, a two-tiered consensus grading system was developed. High-grade MTCs were defined as tumors with at least one of the following features: mitotic index ≥ 5 per 2 mm2, Ki67 proliferative index ≥ 5%, or tumor necrosis. RESULTS: Eighty-one (24.8%) MTCs were high-grade using this scheme. In multivariate analysis, these patients demonstrated decreased overall (hazard ratio [HR] = 11.490; 95% CI, 3.118 to 32.333; P < .001), disease-specific (HR = 8.491; 95% CI, 1.461 to 49.327; P = .017), distant metastasis-free (HR = 2.489; 95% CI, 1.178 to 5.261; P = .017), and locoregional recurrence-free (HR = 2.114; 95% CI, 1.065 to 4.193; P = .032) survivals. This prognostic power was maintained in subgroup analyses of cohorts from each of the five centers. CONCLUSION: This simple two-tiered international grading system is a powerful predictor of adverse outcomes in MTC. As it is based solely on morphologic assessment in conjunction with Ki67 immunohistochemistry, it brings the grading of MTCs in line with other NETs and can be readily applied in routine practice. We therefore recommend grading of MTCs on the basis of mitotic count, Ki67 proliferative index, and tumor necrosis.

11 June 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
BXBin Xu
Bin Xu
MSMaelle Saliba
Maelle Saliba
BABayan Alzumaili
Bayan Alzumaili
MAMohammed Alghamdi
Mohammed Alghamdi
NLNancy Lee
Nancy Lee
Nora KatabiNora Katabi
Nora Katabi

18 March 2025 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
ASAnkur R. Sangoi
Ankur R. Sangoi
SWSean Williamson
Sean Williamson
MOMurat Oktay
Murat Oktay
AGAnthony J. Gill
Anthony J. Gill
Kiril TrpkovKiril Trpkov
Kiril Trpkov
MAMahmut Akgul
Mahmut Akgul

25 July 2025 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
ASAnkur R. Sangoi
Ankur R. Sangoi
SWSean Williamson
Sean Williamson
MOMurat Oktay
Murat Oktay
AGAnthony J. Gill
Anthony J. Gill
Kiril TrpkovKiril Trpkov
Kiril Trpkov
MAMahmut Akgul
Mahmut Akgul